Biotech · Private company
Ariad Pharmaceuticals
Track this companyFree. Adds Ariad Pharmaceuticals to your Dealase workspace and tells you when its record changes.
Clinical trials50 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- BrigatinibPhase 3 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- CrizotinibPhase 3 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- BrigatinibPhase 2 · ALK-positive Advanced NSCLCClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or CeritinibPHASE2 · COMPLETED · started Jan 31, 2019ClinicalTrials.gov NCT03535740 · fetched Nov 12, 2026
- An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG®TERMINATED · started Mar 2, 2018ClinicalTrials.gov NCT02455024 · fetched Nov 12, 2026
- ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) ParticipantsPHASE3 · COMPLETED · started May 26, 2016ClinicalTrials.gov NCT02737501 · fetched Nov 12, 2026
- Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive BiomarkersPHASE2 · COMPLETED · started Sep 24, 2013ClinicalTrials.gov NCT01935336 · fetched Nov 12, 2026
- Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)PHASE2 · TERMINATED · started Apr 1, 2012ClinicalTrials.gov NCT01570868 · fetched Nov 12, 2026